Last updated on April 2018

Study of a new medication for the treatment of Alzheimer's Disease


Brief description of study

This is a Phase I study to assess a new medication in patients with Alzheimer's Disease and periodontitis (gum disease).  Qualified participants will receive at no charge, study related physical exams, EKGs, lab work and study medication.  

Detailed Study Description

The objective of this study is to assess the safety and tolerability of the study drug given orally twice daily for 28 days. The study will also assess the effects of study drug on oral and cerebrospinal fluid biomarkers. The study evaluations include 2 detailed dental examinations and 2 lumbar punctures. The efficacy of the study drug in Alzheimer's disease has not been tested yet.

Clinical Study Identifier: TX203031

Contact Investigators or Research Sites near you

Start Over

Bioclinica Research

Orlando, FL United States
  Connect »

Pacific Research Network, Inc.

San Diego, CA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.